Incyte Corporation (INCY) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Incyte Corporation (INCY) Bundle
Enhance your investment strategies with the Incyte Corporation (INCY) DCF Calculator! Utilize authentic Incyte financial data, adjust growth projections and expenses, and observe how these modifications affect the intrinsic value of Incyte Corporation (INCY) in real-time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,158.8 | 2,666.7 | 2,986.3 | 3,394.6 | 3,695.6 | 4,232.0 | 4,846.3 | 5,549.6 | 6,355.1 | 7,277.5 |
| Revenue Growth, % | 0 | 23.53 | 11.98 | 13.67 | 8.87 | 14.51 | 14.51 | 14.51 | 14.51 | 14.51 |
| EBITDA | 475.7 | -178.2 | 630.2 | 599.6 | 919.4 | 668.6 | 765.7 | 876.8 | 1,004.1 | 1,149.8 |
| EBITDA, % | 22.03 | -6.68 | 21.1 | 17.66 | 24.88 | 15.8 | 15.8 | 15.8 | 15.8 | 15.8 |
| Depreciation | 54.5 | 51.8 | 57.8 | 67.9 | 82.7 | 90.1 | 103.1 | 118.1 | 135.3 | 154.9 |
| Depreciation, % | 2.53 | 1.94 | 1.94 | 2 | 2.24 | 2.13 | 2.13 | 2.13 | 2.13 | 2.13 |
| EBIT | 421.1 | -230.0 | 572.4 | 531.8 | 836.8 | 578.6 | 662.5 | 758.7 | 868.8 | 994.9 |
| EBIT, % | 19.51 | -8.63 | 19.17 | 15.67 | 22.64 | 13.67 | 13.67 | 13.67 | 13.67 | 13.67 |
| Total Cash | 2,117.6 | 1,801.4 | 2,348.2 | 3,239.0 | 3,656.0 | 3,712.5 | 4,251.3 | 4,868.3 | 5,574.9 | 6,384.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 308.8 | 482.0 | 616.3 | 644.9 | 743.6 | 779.8 | 893.0 | 1,022.6 | 1,171.0 | 1,341.0 |
| Account Receivables, % | 14.3 | 18.07 | 20.64 | 19 | 20.12 | 18.43 | 18.43 | 18.43 | 18.43 | 18.43 |
| Inventories | 16.5 | 36.0 | 56.9 | 121.0 | 63.0 | 78.6 | 90.0 | 103.1 | 118.0 | 135.2 |
| Inventories, % | 0.76456 | 1.35 | 1.91 | 3.56 | 1.7 | 1.86 | 1.86 | 1.86 | 1.86 | 1.86 |
| Accounts Payable | 83.6 | 98.8 | 172.1 | 277.5 | 109.6 | 207.2 | 237.3 | 271.7 | 311.2 | 356.4 |
| Accounts Payable, % | 3.87 | 3.7 | 5.76 | 8.18 | 2.97 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 |
| Capital Expenditure | -78.1 | -187.4 | -181.0 | -77.8 | -47.5 | -171.7 | -196.6 | -225.1 | -257.8 | -295.2 |
| Capital Expenditure, % | -3.62 | -7.03 | -6.06 | -2.29 | -1.28 | -4.06 | -4.06 | -4.06 | -4.06 | -4.06 |
| Tax Rate, % | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 | 28.36 |
| EBITAT | 386.6 | -292.9 | 951.8 | 342.4 | 599.4 | 495.0 | 566.9 | 649.2 | 743.4 | 851.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 121.4 | -606.0 | 746.7 | 345.2 | 426.0 | 459.2 | 378.9 | 433.9 | 496.9 | 569.0 |
| WACC, % | 7.8 | 7.8 | 7.8 | 7.79 | 7.79 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,857.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 592 | |||||||||
| Terminal Value | 15,590 | |||||||||
| Present Terminal Value | 10,711 | |||||||||
| Enterprise Value | 12,568 | |||||||||
| Net Debt | -3,175 | |||||||||
| Equity Value | 15,743 | |||||||||
| Diluted Shares Outstanding, MM | 226 | |||||||||
| Equity Value Per Share | 69.68 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Incyte Corporation’s (INCY) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing your time.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Incyte Corporation (INCY).
- WACC Calculator: Pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to Incyte Corporation (INCY).
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for Incyte Corporation (INCY).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Incyte Corporation (INCY).
- Visual Dashboard and Charts: Graphical outputs that summarize key valuation metrics for straightforward analysis of Incyte Corporation (INCY).
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Incyte Corporation (INCY) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Incyte Corporation’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Incyte Corporation (INCY)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, investors, and industry consultants.
- Accurate Data: Incyte’s historical and projected financials integrated for precise calculations.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Detailed step-by-step guidance to navigate the calculator.
Who Should Use Incyte Corporation (INCY)?
- Biotech Investors: Make informed decisions with access to comprehensive research and analytics.
- Healthcare Analysts: Streamline your analysis with ready-to-use financial models tailored for biotech.
- Consultants: Efficiently customize presentations or reports for clients in the pharmaceutical sector.
- Life Sciences Enthusiasts: Enhance your knowledge of biotech investments through detailed case studies.
- Students and Educators: Utilize it as a practical resource in courses focused on biotechnology and finance.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Incyte Corporation (INCY) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Incyte Corporation (INCY).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.